The Bull Case For InnoCare Pharma (SEHK:9969) Could Change Following First-in-China VAV1 Degrader Trial Start

Simply Wall St.03-17

InnoCare Pharma recently dosed the first healthy volunteer in a China clinical trial of ICP-538, an oral VAV1-directed molecular glue degrader for autoimmune diseases, marking the first VAV1 degrader ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2620496361?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-03-17 01:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620496361","market":"sg","top_or_hot":-1,"title":"The Bull Case For InnoCare Pharma (SEHK:9969) Could Change Following First-in-China VAV1 Degrader Trial Start","media":"Simply Wall St.","content":"<div>\n<p>InnoCare Pharma recently dosed the first healthy volunteer in a China clinical trial of ICP-538, an oral VAV1-directed molecular glue degrader for autoimmune diseases, marking the first VAV1 degrader ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9969/innocare-pharma-shares/news/the-bull-case-for-innocare-pharma-sehk9969-could-change-foll\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Bull Case For InnoCare Pharma (SEHK:9969) Could Change Following First-in-China VAV1 Degrader Trial Start</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Bull Case For InnoCare Pharma (SEHK:9969) Could Change Following First-in-China VAV1 Degrader Trial Start\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-17 01:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9969/innocare-pharma-shares/news/the-bull-case-for-innocare-pharma-sehk9969-could-change-foll><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>InnoCare Pharma recently dosed the first healthy volunteer in a China clinical trial of ICP-538, an oral VAV1-directed molecular glue degrader for autoimmune diseases, marking the first VAV1 degrader ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9969/innocare-pharma-shares/news/the-bull-case-for-innocare-pharma-sehk9969-could-change-foll\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9969/innocare-pharma-shares/news/the-bull-case-for-innocare-pharma-sehk9969-could-change-foll","article_id":"2620496361","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9969/innocare-pharma-shares/news/the-bull-case-for-innocare-pharma-sehk9969-could-change-foll","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2620496361","pubTimestamp":1773681741,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"InnoCare Pharma recently dosed the first healthy volunteer in a China clinical trial of ICP-538, an oral VAV1-directed molecular glue degrader for autoimmune diseases, marking the first VAV1 degrader to reach trials in China and only the second globally.\nThis move positions InnoCare at the forefront of a new class of targeted immunology drugs, in an area where no VAV1-focused therapies are yet approved worldwide.\nWe’ll now examine how advancing ICP-538, a first-in-China VAV1 degrader, could...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK4528":"SaaS概念","AIYY":"YIELDMAX AI OPTION INCOME STRATEGY ETF","BK4585":"ETF&股票定投概念","BK1161":"生物科技","BK4023":"应用软件","BK1574":"生物医药B类股","09969":"诺诚健华","AI":"C3.ai, Inc.","BK4543":"AI","BK4551":"寇图资本持仓","BK4587":"ChatGPT概念"},"translate_title":"诺诚健华医药（SEHK：9969）的牛市可能会在中国首个VAV1降解剂试验开始后发生变化","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AI":0.61,"AIYY":0.6,"09969":0.9},"content_text":"InnoCare Pharma recently dosed the first healthy volunteer in a China clinical trial of ICP-538, an oral VAV1-directed molecular glue degrader for autoimmune diseases, marking the first VAV1 degrader to reach trials in China and only the second globally. This move positions InnoCare at the forefront of a new class of targeted immunology drugs, in an area where no VAV1-focused therapies are yet approved worldwide. We’ll now examine how advancing ICP-538, a first-in-China VAV1 degrader, could influence InnoCare Pharma’s evolving investment narrative. This technology could replace computers: discover 24 stocks that are working to make quantum computing a reality.AdvertisementInnoCare Pharma Investment Narrative RecapTo own InnoCare Pharma, you need to believe its heavy R&D spend can convert into a durable portfolio in oncology and autoimmune diseases, reducing reliance on orelabrutinib. The ICP-538 first-in-human dosing adds early but unproven optionality in autoimmune, while nearer term, late-stage programs like mesutoclax and soficitinib still look like the key catalysts. The biggest current risk remains pipeline execution, given high development costs and the concentration of revenues in a few products. The most relevant recent announcement alongside ICP-538 is zurletrectinib’s priority review for pediatric NTRK fusion tumors in China, building on its prior adult approval. Together with ICP-538’s entry into trials, this shows InnoCare trying to broaden its base across oncology and immunology, which could help mitigate single-asset risk if these programs progress successfully and support the company’s stated goal of improving earnings. Yet, while ICP-538 opens a new autoimmune angle, investors should also be aware that... Read the full narrative on InnoCare Pharma (it's free!)InnoCare Pharma's narrative projects CN¥2.9 billion revenue and CN¥70.2 million earnings by 2028. This requires 30.6% yearly revenue growth and a CN¥279.1 million earnings increase from CN¥-208.9 million today.Uncover how InnoCare Pharma's forecasts yield a HK$20.04 fair value, a 67% upside to its current price.Exploring Other PerspectivesSEHK:9969 1-Year Stock Price Chart While ICP-538 hints at upside beyond orelabrutinib, the most bearish analysts still saw risk of profits staying negative even with forecast revenue near CN¥2.7 billion, underscoring how far opinions about execution and margin recovery can diverge and why it is worth weighing several viewpoints before deciding what this new trial really means for you.Explore another fair value estimate on InnoCare Pharma - why the stock might be worth as much as 67% more than the current price!The Verdict Is YoursDon't just follow the ticker - dig into the data and build a conviction that's truly your own.A great starting point for your InnoCare Pharma research is our analysis highlighting 4 key rewards that could impact your investment decision.Our free InnoCare Pharma research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate InnoCare Pharma's overall financial health at a glance.Contemplating Other Strategies?The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 19 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 30 best rare earth metal stocks of the very few that mine this essential strategic resource.Invest in the nuclear renaissance through our list of 87 elite nuclear energy infrastructure plays powering the global AI revolution.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2620496361","isCrawlerRequest":true}